Lung Tensioning Device Coil Treatment in Patients with Severe Emphysema: A Prospective Safety and Feasibility Trial (EFFORT)
Respiration · 2024
DOI: 10.1159/000541366 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Respiration, 2024. Verfasst von Sharyn A Roodenburg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Pulmonary Emphysema, Pneumonectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Currently, there is a lack of bronchoscopic lung volume reduction options that do not depend on fissure integrity. Endobronchial coils have been extensively studied to address this need but exhibited variable patient response and have been discontinued. Lung tension device (LTD) coils represent the next-generation coil treatment. This study aimed to evaluate safety, feasibility, and efficacy of LTD-coil treatment.
Methods
Patients with advanced emphysema and hyperinflation were enrolled at two European sites. LTD-coils (Free Flow Medical, Fremont, CA, USA) were implanted in the two most destructed lobes, as determined by quantitative CT analysis, in two separate procedures. The primary endpoint was 3-month follow-up after the last treatment.
Results
Fourteen patients (50% male, median age 64 years, FEV1 23%predicted, RV 249%predicted) received LTD-coil treatment: 12 received bilateral and 2 unilateral treatment. Six serious respiratory adverse events occurred within the initial 3 months posttreatment, including one device-associated death. Treatment significantly reduced in- and expiratory volume of the treated lobes (−410 [−710, −340], p = 0.004 and −650 [−730, −190] mL, p < 0.001, respectively) and improved quality of life (SGRQ total score −4.6 [−21.0, −2.6], p < 0.001). However, at a group level, no significant improvements in pulmonary function or 6-min walk distance were observed. Responder rates ranged from 18% to 54% for the different endpoints.
Conclusion
This first-in-human study shows that the new LTD-coil procedure is feasible with a safety profile comparable to the previous coil treatment. While the treatment effectively reduced lobar volume and modestly improved quality of life up to 3 months’ follow-up, at a group level it did not significantly enhance pulmonary function or exercise capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
- Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.
Zitieren
APA
Roodenburg, S. A., Klooster, K., Hartman, J. E., Kontogianni, K., Brock, J. M., Dittrich, A. S., van Dijk, M., Koster, T. D., Herth, F. J. F., & Slebos, D. J. (2024). Lung Tensioning Device Coil Treatment in Patients with Severe Emphysema: A Prospective Safety and Feasibility Trial (EFFORT). Respiration. https://doi.org/10.1159/000541366
Vancouver
Roodenburg SA, Klooster K, Hartman JE, Kontogianni K, Brock JM, Dittrich AS, et al. Lung Tensioning Device Coil Treatment in Patients with Severe Emphysema: A Prospective Safety and Feasibility Trial (EFFORT). Respiration. 2024. doi:10.1159/000541366
BibTeX
@article{Roodenburg2024,
author = {Roodenburg, Sharyn A and Klooster, Karin and Hartman, Jorine E and Kontogianni, Konstantina and Brock, Judith M and Dittrich, A Susanne and van Dijk, Marlies and Koster, T David and Herth, Felix J F and Slebos, Dirk-Jan},
title = {Lung Tensioning Device Coil Treatment in Patients with Severe Emphysema: A Prospective Safety and Feasibility Trial (EFFORT)},
journal = {Respiration},
year = {2024},
doi = {10.1159/000541366}
}
EUVIMED